Pathogenesis and management of myeloma bone disease

被引：36

作者：

Christoulas, Dimitrios ^{[1
]}

Terpos, Evangelos ^{[1
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, Athens 11528, Greece

来源：

EXPERT REVIEW OF HEMATOLOGY | 2009年 / 2卷 / 04期

关键词：

bisphosphonates; bone disease; dickkopf; 1; macrophage inflammatory proteins; multiple myeloma; osteoprotegerin; RANKL; KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR; ADVANCED MULTIPLE-MYELOMA; HEPATOCYTE GROWTH-FACTOR; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; VERTEBRAL COMPRESSION FRACTURES; HISTONE DEACETYLASE INHIBITOR; SKELETAL-RELATED EVENTS; FORMATION IN-VITRO; RECEPTOR ACTIVATOR;

D O I：

10.1586/ehm.09.36

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteolytic bone disease is a frequent complication of multiple myeloma, resulting in skeletal complications that are a significant cause of morbidity and mortality It is the result of increased activity of osteoclasts that is not followed by reactive bone formation by osteoclasts Recent studies have revealed novel molecules and pathways that are implicated in osteoclast activation and osteoblast inhibition including the RANKL/osteoprotegerin pathway, macrophage inflammatory proteins and the wingless type signaling pathway These molecules also appear to interfere with tumor growth and survival providing possible targets for the development of novel drugs for the management of lytic disease in myeloma Currently, bisphosphonates are the mainstay of treatment for myeloma bone disease, although several novel agents appear promising This review focuses on recent advances in understanding the biology of bone disease in multiple myeloma, diagnosis and recent progress in treatment options.

引用

页码：385 / 398

页数：14

共 144 条

[31]

CYAJOBI BO, 2003, BLOOD, V102, P311

[32] Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma [J].

Dankbar, B ;

Padró, T ;

Leo, R ;

Feldmann, B ;

Kropff, M ;

Mesters, RM ;

Serve, H ;

Berdel, WE ;

Kienast, J .

BLOOD, 2000, 95 (08) :2630-2636

[33]

Daragon A, 1993, Eur J Med, V2, P449

[34]

DIMOPOULOS M, 2009, LEUKEMIA, DOI DOI 10.1038/LEU200989

[35] Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid [J].

Dimopoulos, M. A. ;

Kastritis, E. ;

Bamia, C. ;

Melakopoulos, I. ;

Gika, D. ;

Roussou, M. ;

Migkou, M. ;

Eleftherakis-Papaiakovou, E. ;

Christoulas, D. ;

Terpos, E. ;

Bamias, A. .

ANNALS OF ONCOLOGY, 2009, 20 (01) :117-120

[36]

Dimopoulos MA, 2000, BLOOD, V96, P2037

[37]

Dimopoulos MA, 2000, ACTA ONCOL, V39, P823

[38]

Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P968

[39] IL-1β expression in IgM monoclonal gammopathy and its relationship to multiple myeloma [J].

Donovan, KA ;

Lacy, MQ ;

Gertz, MA ;

Lust, JA .

LEUKEMIA, 2002, 16 (03) :382-385

[40] RANK is essential for osteoclast and lymph node development [J].

Dougall, WC ;

Glaccum, M ;

Charrier, K ;

Rohrbach, K ;

Brasel, K ;

De Smedt, T ;

Daro, E ;

Smith, J ;

Tometsko, ME ;

Maliszewski, CR ;

Armstrong, A ;

Shen, V ;

Bain, S ;

Cosman, D ;

Anderson, D ;

Morrissey, PJ ;

Peschon, JJ ;

Schuh, J .

GENES & DEVELOPMENT, 1999, 13 (18) :2412-2424

← 1 2 3 4 5 6 7 8 9 10 →